Arcturus Therapeutics’ (ARCT) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $63.00 target price on the biotechnology company’s stock.

ARCT has been the topic of several other research reports. Leerink Partnrs raised Arcturus Therapeutics to a strong-buy rating in a research report on Monday, August 12th. Cantor Fitzgerald reiterated an overweight rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Finally, Leerink Partners initiated coverage on shares of Arcturus Therapeutics in a report on Monday, August 12th. They issued an outperform rating and a $70.00 target price for the company. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of Buy and an average price target of $71.40.

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock opened at $25.25 on Tuesday. The stock’s 50-day moving average is $20.90 and its 200 day moving average is $26.41. Arcturus Therapeutics has a one year low of $17.52 and a one year high of $45.00. The firm has a market cap of $680.03 million, a price-to-earnings ratio of -6.43 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The business had revenue of $49.86 million during the quarter, compared to analysts’ expectations of $21.00 million. During the same period last year, the company posted ($1.98) earnings per share. On average, sell-side analysts expect that Arcturus Therapeutics will post -2.6 EPS for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. bought a new position in shares of Arcturus Therapeutics during the 1st quarter valued at approximately $40,000. Quest Partners LLC grew its holdings in Arcturus Therapeutics by 3,283.5% during the second quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 3,579 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Arcturus Therapeutics in the second quarter worth $142,000. CANADA LIFE ASSURANCE Co raised its stake in shares of Arcturus Therapeutics by 10.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 428 shares during the period. Finally, Public Employees Retirement System of Ohio lifted its position in shares of Arcturus Therapeutics by 63.8% during the 1st quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 1,800 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.